Outcomes of elderly treated with pembrolizumab for metastatic melanoma comparing with younger patients.

e21508Background: Pembrolizumab (PBZ), a monoclonal anti-PD-1, is approved in France since Oct 2015, as a first-line treatment of patients with advanced melanoma. Although this treatment was shown ...